Search company, investor...
Search
NeuroDerm company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

neuroderm.com

Founded Year

2003

Stage

Acq - P2P | Acquired

Total Raised

$20.5M

Valuation

$0000 

About NeuroDerm

NeuroDerm is a clinical-stage pharmaceutical company developing central nervous system (CNS) product candidates that are designed to overcome major deficiencies of current treatments and achieve enhanced clinical efficacy through continuous, controlled administration. In Parkinson's disease, the company has four product candidates in different stages of development which offer a solution for almost every Parkinson's disease patient from the moderate to the very severe stage of the disease. The company has developed a line of LD/CD product candidates administered through small belt pumps that deliver a continuous, controlled dose of LD/CD. The LD/CD line of product candidates includes: ND0612L and ND0612H, delivered subcutaneously, for moderate and for advanced Parkinson's disease patients, respectively, and ND0680 for a subset of severe Parkinson's disease patients whose symptoms have advanced to a more acute stage, requiring even higher doses of LD/CD. In addition NeuroDerm is developing ND0701, a novel subcutaneously delivered apomorphine formulation for patients who suffer from severe Parkinson's disease and who do not respond well to LD/CD. NeuroDerm is headquartered in the Weizmann Science Park, Rehovot, Israel.

NeuroDerm Headquarters Location

3 Pekeris Street, Ruhrberg Science Bldg Bell Entrance, Rabin Science Park

Rehovot, 7670212,

Israel

+972-8-9462729

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

NeuroDerm Patents

NeuroDerm has filed 61 patents.

The 3 most popular patent topics include:

  • Monoamine oxidase inhibitors
  • Neurological disorders
  • Abandoned drugs
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/6/2021

8/16/2022

Graphical user interface elements, Graphical user interfaces, Graphical control elements, Graphical user interface testing, User interfaces

Grant

Application Date

5/6/2021

Grant Date

8/16/2022

Title

Related Topics

Graphical user interface elements, Graphical user interfaces, Graphical control elements, Graphical user interface testing, User interfaces

Status

Grant

Latest NeuroDerm News

Continuous Subcutaneous Infusion of Levodopa/Carbidopa Has Long-Term Safety in Parkinson Disease

Apr 5, 2022

The phase 2b BeyoND study demonstrates the infusion of levodopa/carbidopa (ND0612; Neuroderm, Israel) was safe and well tolerated over a year long period in individuals with Parkinson disease (PD) with motor fluctuations. As reported in 2021, treatment with continuous subcutaneous infusion of levodopa/carbidopa improved good ON time by an adjusted mean of 2.3 hours at month 3 in a24-hour dosing regimen (n = 44) and 2.6 hours in a 16-hour dosing regimen (n = 83). The improvements were maintained over the 12-month study period. Most participants who completed 1 year of treatment (95%)...

  • When was NeuroDerm founded?

    NeuroDerm was founded in 2003.

  • Where is NeuroDerm's headquarters?

    NeuroDerm's headquarters is located at 3 Pekeris Street, Ruhrberg Science Bldg, Rehovot.

  • What is NeuroDerm's latest funding round?

    NeuroDerm's latest funding round is Acq - P2P.

  • How much did NeuroDerm raise?

    NeuroDerm raised a total of $20.5M.

  • Who are the investors of NeuroDerm?

    Investors of NeuroDerm include Mitsubishi Tanabe Pharma, The Elias Group, The Michael J. Fox Foundation, Omrix, Ofakim Hi-Tech Ventures and 4 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.